• Exosomal SNORD52 Promotes M2 Macrophage Polarization via JAK

  2026-07-10

  This study uncovers a key role for exosomal SNORD52 in driving M2 macrophage polarization through activation of the JAK2/STAT6 pathway in hepatocellular carcinoma (HCC). The findings highlight a novel exosome-mediated mechanism of tumor immune modulation, opening new avenues for targeted cancer research and therapeutic intervention.

• Methyl-β-cyclodextrin: Technical Guide for Membrane Studies

  2026-07-09

  Methyl-β-cyclodextrin (SKU C6939) is designed to selectively extract cholesterol and modulate membrane lipid organization in controlled laboratory research. It is not recommended for diagnostic or therapeutic use and must be handled with attention to solubility, storage, and prompt preparation to ensure experimental consistency.

• FOXM1-Driven ceRNA Networks in Female LUAD: Biomarker Discov

  2026-07-09

  This study identifies FOXM1-centric ceRNA networks as critical regulatory elements in female lung adenocarcinoma (LUAD), revealing their impact on disease progression, prognosis, and immunotherapy response. The integration of transcriptomic, bioinformatic, and cellular validation approaches provides new mechanistic insight and suggests promising biomarkers for stratified patient management.

• Annexin V-FITC/PI Apoptosis Assay Kit: Mitochondrial Damage

  2026-07-08

  Explore the Annexin V-FITC/PI Apoptosis Assay Kit for advanced early apoptosis detection, with a unique focus on mitochondrial damage and hepatocyte apoptosis. This article uncovers assay decision principles informed by recent mechanistic research.

• FASN Inhibition Primes Cancer Cells for Bcl-2-Targeted Apopt

  2026-07-08

  The study uncovers how fatty acid synthase (FASN) inhibition increases mitochondrial apoptotic priming in cancer cells, making them more sensitive to Bcl-2 family inhibitors such as ABT-263 (Navitoclax). These findings inform rational combination strategies for enhancing apoptosis in cancer models.

• Lovastatin as a Translational Probe: Bridging Mechanism to I

  2026-07-07

  Explore how Lovastatin, a potent HMG-CoA reductase inhibitor, unlocks new opportunities for translational researchers. This thought-leadership article blends mechanistic insights from mammalian and plant systems, practical protocol guidance, and competitive product intelligence to help drive innovation in cholesterol metabolism, apoptosis, and cancer research workflows.

• Caffeine in Molecular Research: Mechanisms, Models, and Meta

  2026-07-07

  Explore the scientific foundations of Caffeine (1,3,7-trimethylpurine-2,6-dione) as a research tool in cancer biology and metabolic regulation. This article reveals new mechanistic insights and protocol guidance, bridging molecular action to practical laboratory application.

• ICAA Attenuates Cardiac Hypertrophy via RIP3/CaMKII Inhibiti

  2026-07-06

  This study identifies isochlorogenic acid A (ICAA) as a direct inhibitor of RIP3, suppressing the RIP3/CaMKII pathway and mitigating angiotensin II-induced cardiac hypertrophy in vitro and in vivo. The findings establish RIP3 as a novel therapeutic target, broadening mechanistic strategies for cardiovascular disease research.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-07-06

  Unlock uncompromising protein phosphorylation preservation with Phosphatase Inhibitor Cocktail 1 (100X in DMSO) from APExBIO. This advanced alkaline phosphatase inhibitor empowers high-fidelity phosphoproteomics and signaling studies—even in challenging sample types—by safeguarding phosphorylation states throughout every workflow step.

• Bleomycin Sulfate: Mechanistic Benchmarks in Pulmonary Fibro

  2026-07-05

  Bleomycin Sulfate is a validated DNA strand break inducer widely used in cancer and pulmonary fibrosis research. Its mechanism involves metal ion-dependent oxidative DNA cleavage, resulting in potent cytotoxicity and fibrosis modeling. Peer-reviewed evidence and workflow data support its reproducibility as an anticancer and fibrosis agent.

• 2-Deoxy-D-glucose: Dissecting Glycolysis for Targeted Resear

  2026-07-04

  Explore how 2-Deoxy-D-glucose (2-DG) enables advanced manipulation of glycolysis in cancer, virology, and metabolic studies. This article uniquely connects mechanistic insights to practical experimental design, referencing pivotal bone metabolism research.

• YM 58483 (BTP2): Precision SOCE Blockade in Fibrosis & Immun

  2026-07-03

  YM 58483 (BTP2) is redefining how researchers dissect store-operated calcium entry (SOCE) in fibrosis and immune signaling models, enabling targeted, reproducible inhibition of CRAC and TRP channels. Recent breakthroughs highlight its pivotal role in unraveling ORAI2-driven fibrogenesis, providing both mechanistic clarity and translational promise.

• N4-Acetylcytidine: Unlocking Structural Mechanisms for RNA M

  2026-07-03

  Explore how N4-Acetylcytidine advances RNA modification research through unique structural insights and practical assay design. This in-depth article reveals underappreciated mechanistic findings for RNA epigenetics and post-transcriptional studies.

• AG-221 (Enasidenib): Precision Targeting of Metabolic Vulner

  2026-07-02

  Explore the science behind AG-221 (Enasidenib), a leading IDH2 inhibitor for acute myeloid leukemia research. This article uniquely bridges metabolic rewiring insights with advanced assay design and practical applications, offering a deeper perspective for translational scientists.

• NADH in Redox Sensing and Metabolic Engineering: Novel Insig

  2026-07-02

  Explore the multifaceted research applications of NADH (Reduced-form Nicotinamide Adenine Dinucleotide) as a central coenzyme and dynamic redox sensor. This article delves into its mechanistic roles, advanced biosensor innovations, and practical assay strategies in metabolic engineering.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page